Skip to main content

Table 1 Demographic and clinical characteristics of the patients with post-COVID-19 syndrome

From: The effect of comprehensive rehabilitation on post-COVID-19 syndrome

 

Patients (n = 39)

Age (years)a

59.7.0 ± 15.6

Gender

 Female

15 (38.5%)

 Male

24 (61.5%)

BMI (kg/cm2)a

24.4 ± 3.9

Marital status

 Married

29 (74.4%)

 Single

10 (25.6%)

Education period (years)a

7.6 ± 3.9

Smoking

 Yes

10 (25.6%)

 No

29 (74.4%)

Working Status

 

 Working

7 (17.9%)

 Retired

18 (46.2%)

 Not working

14 (35.8%)

Vaccination

 

 Vaccinated

20(51.3%)

 Unvaccinated

19(48.7%)

History of O2 requirement

 

 Nasal O2

31(79.5%)

 High-flow O2 therapy

30(76.9%)

 Reservoir mask

31(79.5%)

 Intubation

12(30.8%)

Need for ICU (n,%)

33(84.6%)

Diagnosis

 Pulmonary involvement

29 (74.4%)

 Cerebrovascular disease

7 (17.9%)

 CIP/CIM

7 (17.9%)

 Transverse myelitis

1 (2.6%)

 GBS

1 (2.6%)

 Anoxic brain injury

1 (2.6%)

Comorbidities

 HT

18 (46.3%)

 DM

10 (25.7%)

 Cardiovascular disease

10 (25.7%)

 Chronic respiratory disease

5 (12.9%)

 Malignancy

2 (5.1%)

 Others

10 (25.7%)

Post-COVID symptoms

 Dyspnea

30 (76.9%)

 Fatigue

27 (69.2%)

 Myalgia

25 (64.1%)

 Cognitive symptoms

16 (41.0%)

 Genitourinary symptoms

11 (28.2%)

 Chest pain

6 (15.4%)

 Arthralgia

4 (10.3%)

 Gastrointestinal symptoms

3 (7.7%)

Complications

 Muscle atrophy-weakness

19(48.7%)

 Pressure ulcers

6(15.4%)

 Dysphagia

6(15.4%)

 Electrolyte imbalance

5(12.8%)

 Pulmonary embolism

2(5.1%)

 Gastrointestinal bleeding

2(5.2%)

 Pneumothorax

1(2.6%)

 Hypertension

1(2.6%)

 Arrhythmia

1(2.6%)

Length of stay in rehabilitation service

37.5 ± 17.6

Need of O2 requirement (n,%)

15(38.4%)

  1. BMI Body mass index, CIP/CIM Critical illness polyneuropathy critical illness myopathy, GBS Guillain–Barre syndrome; chronic respiratory disease: asthma, chronic obstructive pulmonary disease; cardiovascular disease: heart failure, ischaemic heart disease, arrhythmias, valvular disease; malignancy: bone tumor; Vaccination; sinovac PiCoVacc and Pfizer BNT162b2
  2. aMean ± standard deviation,